Caris Biopharma Partnering
Inform and Empower your Precision Oncology Programs
Have confidence Caris will provide you with the complete picture
Caris leverages leading molecular science and artificial intelligence to redefine cancer which helps drive the development and commercialization of new therapies.
PRECISION PARTNERING
Delivering value across the full life cycle of biopharma therapeutics
INFORM with insights from the industry’s most comprehensive clinico-genomic database
- Comprehensive WES & WTS data
- Matched clinico-genomic data (CODEai™)
- Machine learning & AI
- Expansive tissue and slide repository
EMPOWER through Precision Partnering with customizable offerings
- An answer for both sample types: tissue or blood
- One platform for clinical trials and real-world data
- State-of-the-art equipment and facilities
- Global regulatory and commercial capabilities
DEDICATED BIOPHARMA TEAMS FOR YOU
Our partners are our priority because we want to help you deliver on the promise of precision oncology
- Diverse experience across biopharma and diagnostic industry
- Expertise in molecular science, clinical development, medical affairs, CDx, and commercial
- Thought partnership with our experts in medical, bioinformatics, translational medicine, and regulatory
- Passionate and engaged team tailored for each partner
MATCHED CLINICO-GENOMIC PROFILES
RESIDUAL
FFPE
SLIDES
BIOPHARMA PARTNERSHIPS SINCE 2021
PARTNER THERAPUETICS EMPOWERD BY CARIS
PRECISION DEVELOPMENT
WES & WTS (22,000 genes) provide assurances to accelerate your development programs with data-driven decisions.
Unmatched breadth and depth of profiling coverage from a single platform enables a seamless transition from clinical trial data to real world applications.
Tissue profiling: Analyze DNA, RNA, and proteins through Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and IHC.
LEARN MORE >
Blood-based profiling: Overcome the challenges of insufficient material, poor sensitivity and false positives by analyzing DNA, RNA, and identifying somatic CHIP mutations.
MI Trials: Accelerate enrollment by identifying biomarker+ patients from our extensive network of clinical sites, supported by dedicated clinical trial navigators.
LEARN MORE >
RWE projects: Access a dedicated cross-functional team to address questions and enhance programs by leveraging Caris’ matched clinico-genomic database.
LEARN MORE >
CARIS CDX
Enable the future of precision medicine with a platform built to last.
- Co-partnership provides an optimal approach of developing, validating and launching your novel CDx biomarker
- Comprehensive tests and associated services enable the development of multigene signatures and complex biomarkers
- Support for clinical development and registration trials
- Tissue enrichment maximizes test success and insights
- IUO materials and validation experience to de-risk development and registration process
- Established routine clinical testing accelerates timelines and supports dynamic biomarker strategies
- Established Caris commercial reach can seamlessly bridge clinical investigations and global launches
- MI Insights: Biomarker based alert system for therapeutic commercial success
- Opportunity for coordinated market access and medical education initiatives
REAL WORLD DATA, CARIS CONTEXT
Uncover the complete molecular and clinical context to deliver on the promise of precision medicine.
Caris has amassed a longitudinal multiomic data library that spans over 275k+ patients across 55+ indications. Biopsies come to Caris for sequencing across the standard of care. Our partners can interrogate the data to understand the tumor biology within the context of clinical care. Caris RWD is an unmatched resource for discovery and developmental programs. Data available includes, but is not limited to:
- WES & WTS
- Imaging (IHC, H&E)
- Treatments (e.g. medication, including surgery, radiation)
- Outcomes (e.g. progression events, responses, death)
- Key demographics
ACTIONABLE INSIGHTS FOR BIOPHARMA CAN BE UNLOCKED BY FIVE CORE DATA PILLARS
Caris Discovery
Identifying novel therapeutic targets in oncology is a critical unmet need. Our proprietary end-to-end discovery platform coupled with deep genomic and matched clinical information will enhance your ability to identify and validate novel targets. Partnering with Caris will help accelerate the discovery and delivery of novel therapies to patients. Learn more about Caris’ unparalleled data, innovation lab, and broad footprint.
MI Trials
MI Trials offer patients and physicians access to the latest drugs being developed to improve clinical outcomes. However, awareness of available trials is low and overall participation in oncology trials is less than five percent. Caris helps increase awareness and participation of clinical trials through Caris Trial Solutions.
Right-in-Time Research
Right-In-Time (RIT) research is a rapid start-up/enrollment process where research sites screen for patients prior to activation. The purpose of the program is to reduce the burden on research facilities, which allows them access to a larger number of potential trials when they have an eligible patient. This allows physicians at Caris RIT sites to include clinical trials, not yet opened, in their treatment options for current and future patients.